- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin icodec, Insulin glargine U100
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 13
- States / cities
- Walnut Creek, California • Roswell, Georgia • Idaho Falls, Idaho + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–42
of 18
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Insulin icodec, Insulin glargine, Insulin aspart
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 877 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 103
- States / cities
- Cullman, Alabama • Concord, California • Escondido, California + 85 more
- Conditions
- Type 2 Diabetes
- Interventions
- Tirzepatide, Insulin Lispro (U100)
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,428 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 40
- States / cities
- Sheffield, Alabama • Fresno, California • Huntington Park, California + 36 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- HOE901-U300 (Insulin Glargine 300 U/ml), Lantus (Insulin Glargine 100 U/ml), Mandated back ground therapy
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 638 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 99
- States / cities
- Little Rock, Arkansas • Concord, California • Escondido, California + 80 more
- Conditions
- Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
- Interventions
- Insulin Efsitora Alfa, Insulin Lispro (U100), Insulin Glargine (U100)
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 730 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 24
- States / cities
- Hamden, Connecticut • Clearwater, Florida • Miami Lakes, Florida + 19 more
- Conditions
- Type 1 Diabetes
- Interventions
- Portal Insulin U-500, Humulin R U-500, Lyumjev U-100 Insulin
- Drug
- Lead sponsor
- Portal Diabetes, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Type 1 Diabetes, Type 2 Diabetes
- Interventions
- AID system with Remote Real-Time CGM, Standard of Care Insulin Therapy + CGM
- Device · Combination Product
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 3
- States / cities
- Stanford, California • Atlanta, Georgia • Charlottesville, Virginia
- Conditions
- Type 2 Diabetes
- Interventions
- Insulin glargine/lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Metformin (Background Drug)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 736 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 108
- States / cities
- Birmingham, Alabama • Sun City, Arizona • Tempe, Arizona + 91 more
- Conditions
- Mild Cognitive Impairment, Cognitive Impairment
- Interventions
- Insulin, Placebo, intranasal nebulizer-like device
- Drug · Other · Device
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin Peglispro, Insulin Glargine, Insulin Lispro
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Insulin Aspart SAR341402, Insulin Aspart, Insulin glargine U100
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 33
- States / cities
- Concord, California • Temecula, California • Ventura, California + 30 more
- Conditions
- Diabetes Mellitus
- Interventions
- LINjeta U-100 Insulin, Humalog U-100
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 50 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 2
- States / cities
- Stanford, California • Denver, Colorado
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 878 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 117
- States / cities
- Montgomery, Alabama • Chandler, Arizona • Mesa, Arizona + 93 more
- Conditions
- Type 2 Diabetes
- Interventions
- Glargine U300, Glargine U100, Glulisine Insulin
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 247 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Minneapolis, Minnesota • Cleveland, Ohio
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- HOE901-U300 (Insulin glargine new formulation), Lantus (Insulin glargine)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 549 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 82
- States / cities
- Chandler, Arizona • Little Rock, Arkansas • Bell Gardens, California + 71 more
- Conditions
- Type 2 Diabetes, Type 2 Diabetes Mellitus
- Interventions
- VGo
- Device
- Lead sponsor
- East Coast Institute for Research
- Network
- Eligibility
- 21 Years and older
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Macon, Georgia
- Conditions
- Diabetes, Type 2
- Interventions
- Insulin icodec, Insulin glargine
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 412 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 27
- States / cities
- Fresno, California • Hawthorne, California • La Jolla, California + 23 more
- Conditions
- Type1diabetes
- Interventions
- Aspart insulin
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 9 Years to 15 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut